SYLLABUS

Therapeutics III
PHAR 671
School of Pharmacy
Spring, 2015

This syllabus is not to be construed as a contract with the student and is subject to change.

The School of Pharmacy reserves the right to change the course syllabus. The School should notify the
students through the course notification system or by an email preferably through the Blackboard system

Materials used in this class may be copyrighted and should not be shared with individuals not enrolled

.
Course meeting days and Tuesdays (3-5:15pm), Wednesdays (3:45-5:15pm), Thursdays (3:45-5:15pm)
time
Location Studio Classroom (SC) L10
Team Leader / Instructor Aaron Sizemore, PharmD, BCPS
Office CEB 149
Phone 304-399-7642 (St. Mary’s)
Email Sizemorej@marshall.edu
Office hours Friday 12 PM and by appointment

Faculty Email Office Phone Office Hours /

Number Appointments accepted?
Stephanie Anderson, andersons@marshall.edu 151 304-696-7397 Wednesdays 1pm-2pm
PharmD CEB
Inder Sehgal, DVM, PhD sehgali@marshall.edu 226 304-696-3520
CEB
Eric Blough, PhD blough@marshall.edu 208 304-696-2708 By appointment
CEB
Each faculty member will be available to meet with students outside of office hours by appointment

Student: If the instructor accepts appointments, then please email the instructor for availability. The
student can expect the instructor to respond to E-mails and phone messages within 72 hours.

Course Description: Students will learn about the therapeutic use of medication and non-medication
interventions for both treatment and prevention of cardiovascular diseases, renal diseases, pulmonary diseases,
and associated electrolyte disorders. Exploration of normal human physiology, disease pathophysiology, and the
pharmacologic and chemical properties of medications will precede discussions of therapeutic use. This course
will emphasize performance of the activities of the pharmacist as a health care provider. Activities emphasized
include patient assessment, consultation monitoring, communication, drug effectiveness (safety, interactions,
and adverse events) and the professional and legal dynamics encountered in pharmacy practice.

Page 1 of 18
Prerequisites: P-2 status

Text Books:
Required:

Dipiro, JT, Talbert, RL, et. al. Pharmacotherapy: A Pathophysiologic Approach, 8th ed. McGraw-Hill
Medical. 2011. ISBN-10: 0071703543 | ISBN-13: 978-0071703543

Brunton L et al. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 12th ed. ISBN -10:
0071624422 ISBN – 13: 978-0071624428

Schwinghammer T, et al. Pharmacotherapy Casebook: A Patient-Focused Approach, 8th ed. ISBN – 10:
0071746269 ISBN-13: 978-0071746267

Course Objectives:

Number Objective Linkage to How Assessed

MUSOP
Abilities
(list ability
numbers)
1 Obtain, organize, interpret, and evaluate patient- 1,5,6,7,44 Examination
specific information needed to prepare a patient care IRAT/GRAT
plan or to identify, prevent, and resolve drug therapy Active Learning Exercise
problems.

2 Interpret and evaluate pharmacology and 1,5,6,7 Examination

pharmaceutical related information, including drug IRAT/GRAT
dosage form, delivery system, drug-drug Active Learning Exercise
interactions, and drug-nutrition interactions, needed
to prepare the care plan.

3 Prepare an individualized patient care plan and 1,5,6,7,8,45 Examination

adjust or modify the care plan as needed based on IRAT/GRAT
patient specific parameters. Active Learning Exercise

4 Perform ongoing patient monitoring, evaluation, and 1,5,6 Examination

follow-up to identify pharmacotherapy related IRAT/GRAT
problems or patient adherence issues. Active Learning Exercise

5 Provide counseling to patients on the proper use, 1,6,20 Examination

side-effects, storage, and handling of medications to IRAT/GRAT
ensure the patient’s care plan is successful. Active Learning Exercise

Page 2 of 18
 6 Educate patients and/or caregivers on non- 1,8,20 Examination
pharmacological and lifestyle modifications to help IRAT/GRAT
ensure the patient care plan is successful. Active Learning Exercise

7 Describe the basic anatomy and pathophysiology of 1 Examination

different cardiovascular, pulmonary, renal and IRAT/GRAT
electrolyte disorders. Active Learning Exercise

8 Describe the pharmacology and pharmacokinetics of 1,5,6,7 Examination

the various agents that are used to manage IRAT/GRAT
cardiovascular, renal, pulmonary, and electrolyte Active Learning Exercise
disorders.

9 Analyze and interpret scientific literature and other 1,7,8,56 Examination

information in order to draw best evidence IRAT/GRAT
conclusions that address specific needs or problems. Active Learning Exercise

Schedule of Activities:

Date Meeting Meeting Topic Course Student Learning Outcomes Instructor

Format
Week 1 SC Introduction to  Describe the general mechanisms by which Sehgal
Jan 13 principles and drugs exert their effects in biological systems
Tue 3:00- concepts of (7)
5:15 PM pharmacology
 Apply terminology associated with receptors
and enzymes which are drug targets (8)

 Utilize pharmacologic terminology such as

agonist, antagonist, receptor, affinity, potency,
efficacy, additive, synergistic, tolerance,
tachyphylaxis and dissociation (8)

 Classify common drug inhibitory mechanisms

by their effects on agonist function (8)

 Apply principles of the quantal dose response

curve to drug efficacy and toxicity (8)
Jan 14 SC Introduction to  Compare and contrast the advantages and Sehgal
Wed principles of drug disadvantages of different routes of drug
3:45-5:15 distribution administration. (7)
PM
 Apply components of drug physicochemistry to
determining drug distribution (8)

Page 3 of 18
  Discuss how volume of distribution,
partitioning and metabolism determine a drug’s
dosing regimen (8)
Jan 15 SC Cardiology  Compare and contrast the cellular mechanisms Blough
Thur pathophysiology I underlying the pathophysiology of vascular
3:45-5:15 disease, arteriosclerosis, atherosclerosis, and
PM hypertension (7)

 Describe cardiac structure, the cardiac cycle and

cardiac output (7)
Week 2 SC Cardiology  Describe the cellular mechanisms underlying Blough
Jan 20 pathophysiology II the pathophysiology of dilated cardiomyopathy,
Tue 3:00- hypertrophic cardiomyopathy, restrictive
5:15 PM cardiomyopathy, left sided heart failure and
right sided heart failure (7)
Jan 21 SC Pharmacology of  Identify similarities and differences between Sehgal
Wed antihypertensives I mechanisms of action of antihypertensives
3:45-5:15 which act by inhibiting biologic targets (8)
PM
 List major adverse effects associated with
common antihypertensive agents (8)

 Compare and contrast physiologic and

pathophysiologic roles of angiotensin,
adrenergic and calcium channel receptors in
hypertension (7)

 Classify diuretics by site of action and by

mechanism (8)
Jan 22 SC Pharmacology of  Summarize the pathophysiology of pulmonary Sehgal
Thur antihypertensives artery hypertension (7)
3:45-5:15 II and PAH
PM  Describe the pharmacology new pathway-
selective agonists/antagonists used in the
treatment of IPAH (8)

 Describe the cellular mechanism of action of

endothelin antagonists, PDE-5 inhibitors and
prostacyclin receptor agonists (8)

 Apply knowledge of eicosanoid family

metabolism to determine potential drug
interactions between prostacyclins and NSAIDs
(8)
Week 3 SC Pharmacology of  Differentiate between prevention and therapy of Sehgal
Jan 27 coronary artery coronary artery disease (7)
Tue 3:00- disease I
5:15 PM  Describe the mechanism of action of HMG
CoA reductase inhibitors and nitrates (8)
Page 4 of 18
Jan 28 SC Pharmacology of  Discuss the pathophysiologies of STEMI and Sehgal
Wed coronary artery non-STEMI (7)
3:45-5:15 disease II
PM  Relate the pathophysiologies of STEMI and
NSTEMI to the pharmacologic agents used in
therapy (7,8)

 Explain the mechanisms of common

antithrombotics (8)

 Research and explain mechanisms and adverse

effects of novel antithrombotics now on the
market (7,8)
Jan 29 SC Pharmacology of  Describe the major ion fluxes (K+, Na+ & Ca Sehgal
Thur antiarrhythmics I 2+ ) during depolarization-repolarization (7)
3:45-5:15
PM  List pharmacologic means which are used to
decrease the automaticity of ectopic
pacemakers. (8)

 Compare the mechanism of class I

antiarrhythmics sub-types with expected effects
on the ECG (8)

 Segregate class I antiarrhythmics into those

used primarily for atrial or ventricular
antiarrhythmics (8)

 Outline the molecular mechanism of class II

antiarrhythmics (8)
Week 4 SC Pharmacology of  Recall other cardiovascular diseases which are Sehgal
Feb 3 antiarrhythmics II treated with class II antiarrhythmics agents (8)
Tue 3:00-
5:15 PM  Describe the mechanism of class III
antiarrhythmics (8)

 Compare the mechanism of sotalol with other

class III antiarrhythmics (8)

 Predict adverse effects associated with

antiarrhythmics (8)

 Define the unique adverse effects associated

with amiodarone (8)

 Describe the arrhythmias targeted by, and

contraindications of, class IV antiarrhythmics
(Ca2+ channel blockers) (7,8)

Page 5 of 18
Feb 4 SC Pharmacology of  List compensatory mechanisms in heart failure Sehgal
Wed heart failure, which complicate the disease (7)
3:45-5:15 venous
PM thromboembolism,  Describe the pharmacology of drugs used in
stroke, and heart failure (8)
hypovolemic
shock  Outline mechanisms and adverse effects
associated with positive inotropics (2,8)

 Explain the pathology and genesis of TE (7)

 Differentiate between the mechanisms of

heparin and other clotting inhibitors (7,8)

 Describe the treatment and prevention of

ischemic stroke and general treatment of
hypovolemic shock (7)
Feb 5 Pharmacology of  Define the physiologic role of lipid transport (7) Sehgal
Thur lipid disorders
3:45-5:15  Describe the pathophysiologies associated with
PM lipid transport (7)

 Differentiate between the mechanisms of

HMG-CoA reductase inhibitors and sterol-
absorption inhibitors or bile resins (7,8)

 Outline the molecular mechanistic similarities

between fibric acids and steroid molecules (8)
Feb 9 Exam I
Monday
6pm-8pm
Week 5 SC Hypertension and  Identify cardiovascular (CV) complications that S. Anderson
Feb 10 Hypertensive are associated with hypertension (hypertension-
Tue 3:00- crises related target organ damage) and list major CV
5:15 PM risk factors (1).

 Recommend lifestyle modifications for the

management of hypertension, and describe the
effectiveness of these modifications (2,3,4,5,6)

 Create or adjust a drug therapy regimen and

monitoring plan for a given patient scenario
(2,3,4,5, 8)

 Compare and contrast the goals of treatment

and pharmacotherapy for managing
hypertensive urgency and emergency (2,3,4,5)
Feb 11 SC Heart failure  List the signs and symptoms of heart failure (1) Sizemore

Page 6 of 18
Wed
3:45-5:15  Design an appropriate pharmacotherapy
PM regimen for a patient with heart failure
(1,2,3,4,5,6)

 Recommend changes in the pharmacotherapy

regimen to positively impact the patient’s
morbidity and mortality (1,2,3,4,5,6)

 Describe the use and monitoring of diuretics,

ACEIs, ARBs, BBs, aldosterone antagonists,
hydralazine, nitrates, and digoxin in heart
failure (4)

 Differentiate treatment modalities for heart

failure with preserved ejection fraction and
heart failure with reduced ejection fraction
(1,2,3,4,5,6,9)
Feb 12 SC Acute  Determine potential causes of heart failure Sizemore
Thur Decompensated exacerbations (1)
3:45-5:15 Heart Failure
PM  Differentiate the role of inotropic agents in
patients with heart failure (8)

 Recommend a pharmacotherapy regimen based

on various hemodynamic subsets of a patient
(2,3,4,5,6)

Week 6 SC Atrial Fibrillation  Explain the pathophysiologic mechanisms for Sizemore

Feb 17 underlying major arrhythmias and identify them
Tue 3:00- on an EKG (7)
5:15 PM
 Identify risk factors for stroke in atrial
fibrillation and develop an appropriate
treatment regimen for a patient (1,2,3,4)

 Describe rate vs. rhythm control in atrial

fibrillation (1)

 Differentiate between the various

anticoagulants that are used for stroke
prevention in atrial fibrillation (2,3,8)
Feb 18 SC Dyslipidemia  List the recommendations for screening adults S. Anderson
Wed for lipid disorders (1)
3:45-5:15
PM  List the four instances statin therapy is
indicated according to the 2013 AHA/ACC
Guideline on the Treatment of Blood
Page 7 of 18
 Cholesterol to Reduce Atherosclerotic
Cardiovascular Risk in Adults (1)

 Compare and contrast available lipid

medications (4,5,7,8)

 Create or adjust a drug therapy regimen and

monitoring plan for a given patient scenario
(2,3,4,5,8)

 List the lifestyle modifications recommended

for a patient with dyslipidemia (5,6)

 List the secondary causes of dyslipidemia (7)

Feb 19 SC Peripheral arterial  Describe and interpret the diagnosis of PAD Sizemore
Thur disease using objective data, physical findings, and
3:45-5:15 clinical testing (1,2)
PM
 Provide lifestyle recommendations for patients
with PAD (5,6)

 Describe goals of therapy for patients with PAD

(2)

 Formulate a therapeutic plan for a patient with

PAD (1,2,3,4,5)
Week 7 SC Acute Coronary  Differentiate between STEMI, NSTEMI, and Sizemore
Feb 24 Syndromes unstable angina based on symptoms, lab results,
Tue 3:00- and EKG findings (7)
5:15 PM
 List time to treatment goals for PCI and
administration of fibrinolytic therapy for
patients with STEMI (1)

 Devise a pharmacotherapy treatment plan for

patients with UA/NSTEMI and STEMI
(1,2,3,4,5)

 Differentiate between and identify patients who

are candidates for various antiplatelet agents
post MI (1,2)

 Explain the consequences of poor adherence to

secondary prevention therapies following MI
(5,6,7)
Feb 25 SC Ischemic heart  List the major determinants for myocardial Sizemore
disease oxygen demand (7)
Page 8 of 18
Wed
3:45-5:15  Define the major risk factors for ischemic heart
PM disease (1)

 Describe the clinical presentation of ischemic

heart disease (1,2,)

 Develop a pharmacological treatment plan for a

patient with ischemic heart disease (2,3,4,5,6)
Feb 26 SC Cardiac Arrest  List the pharmacologic agents used to treat Sizemore
Thur patients with ventricular fibrillation (VF) or
3:45-5:15 ventricular tachycardia (VT) (7,8)
PM
 List the pharmacologic agents used in
asystole/PEA (8)

 Formulate a pharmacologic treatment plan for a

patient with VF, VT or asystole/PEA (1,2,3,4,5)

 Discuss the various routes of administration

used in cardiac arrest (1)

 Compare and contrast vasopressors, inotropes,

and vasopressin and their side effects (8)

 Identify major types of cardiac arrhythmias on

an EKG (7)

 List the major drugs that are known to prolong

the QT interval and their possible consequences
(1)
Feb 27 Exam II
Friday
11am-
1pm
Week 8 SC Venous  Recognize the signs and symptoms of deep vein Sizemore
Mar 3 thromboembolism thrombosis and pulmonary embolism (1,2)
Tue 3:00-
5:15 PM  Compare and contrast antithrombotic agents (8)

 Formulate a treatment plan for a patient who

develops venous thromboembolism (2,3,4,5)

 Identify warfarin drug-drug and drug-food

interactions (1,2,8)

 Develop an education and counseling plan for a

patient receiving antithrombotic therapy (5,6)

Page 9 of 18
  Interpret and select laboratory tests commonly
used to monitor antithrombotic therapy (1,2)
Mar 4 SC Stations/Cases/Rev S. Anderson
Wed iew Sizemore
3:45-5:15
PM
Mar 5 SC Pathophysiology  List basic functions of the kidney (7) Sehgal
Thur of acute renal
3:45-5:15 disease and  Explain electrolyte transmembrane transport in
PM electrolyte the nephron (7)
imbalances
 Define the net effects of renal filtration (7)

 Explain the relevance of creatinine and creatine

clearance in diagnosis, prognosis of renal
disease and drug therapy (7)

 Predict other organ systems that will be affected

by renal failure (7)

 Explain common etiologies and remedies for

electrolyte imbalances (7,8)
Week 9 SC Pathophysiologies  Define chronic renal failure (7) Sehgal
Mar 10 of chronic renal
Tue 3:00- disease and  List major causes of chronic renal failure in the
5:15 PM pharmacology of U.S. (1,2)
renal failure
 Be able to apply terminologies of nephrotic
syndrome, glomerulonephritis, diabetic
nephropathy and nephrotoxicity (7)

 List the electrolyte imbalances expected to

accompany acute and chronic renal failure (7)

 Discuss pharmacologic options used to treat

symptoms of chronic renal failure (8)
Mar 11 SC Pharmacology of  Explain the mechanism for common Sehgal
Wed cardiotoxic and nephrotoxic drugs including NSAIDs and ACE
3:45-5:15 nephrotoxic drugs inhibitors (7,8)
PM
 Instruct on the nephrotoxicity of agents such as
cisplatin, radiocontrast media, immunoglobines,
immunosuppressants, amphotericin B (7,8)
Mar 12 SC Pharmacology of  Compare and contrast the pathophysiology of Sehgal
Thur incontinence incontinence and differences between genders
3:45-5:15 related to pathophysiology (7)
PM
 Define major forms of incontinence (1)

Page 10 of 18
  Differentiate between pharmacologic treatments
for stress and urge incontinence (8)

 Compare the mechanistic differences between

anticholinergics and alpha agonists in the
therapy of incontinence (8)

 Prepare a discussion of adverse effects

associated with drugs used to treat
incontinence. (2,8)
March 13 Exam III
Friday
11am-
1pm
3-16-15 - Spring Break
3-20-15
Week 10 SC Acute Kidney  Determine the type of acute kidney injury a Sizemore
Mar 24 Injury patient is experiencing using patient history and
Tue 3:00- laboratory findings (1,7)
5:15 PM
 Recommend measures to minimize the
development of AKI for patients receiving
contrast agents (1,2,3,4)

 Provide a patient specific pharmacotherapy and

monitoring plan for a patient with established
AKI (1,2,3,4)
Mar 25 SC Incontinence  Compare and contrast the clinical presentations S. Anderson
Wed of the main types of urinary incontinence (1)
3:45-5:15
PM  Identify those drugs that can precipitate new-
onset or aggravate existing urinary incontinence
(1,2,5)

 Compare and contrast the nonpharmacologic

treatments of the main types of urinary
incontinence (1,5,6)

 Select an appropriate drug for urinary

incontinence based on patient-specific data
(1,2,3,4)

 Create or adjust a drug therapy regimen and

monitoring plan for a given patient scenario
(1,2,3,4,5,8)
Mar 26 SC Acid-Base  Determine the likely cause of an acid-base Sizemore
Thur Disorders disorder based on patient history, atrial blood
gas, and medication history (1,2,7)
Page 11 of 18
3:45-5:15
PM  Differentiate the likely type of acid-base
disorder (1)

 Determine the likely type of metabolic acidosis

based on serum anion gap (1,7)

 Develop a therapeutic plan for patients with

various types of acid-base disorders (1,2,3,4)
Week 11 Chronic Kidney  Define the stages of kidney disease and the Sizemore
Mar 31 Disease signs and symptoms that accompany them (1)
Tue 3:00-
5:15 PM  Develop a pharmacotherapeutic treatment and
monitoring plan for patients with chronic
kidney disease (2,3,4)

 Explain the importance and risks of anemia

management in patients with chronic kidney
disease and discuss management strategies (1,2)

 Design appropriate treatment regimens for

CKD-mineral and bone disorders (1,2,3,4)

 Compare and contrast the different types of

hemodialysis modalities (7)
April 1 SC Dialysis  Compare and contrast different types of dialysis S. Anderson
Wed (10)
3:45-5:15  Identify complications associated with dialysis
PM (!0)
 Identify pharmacologic and nonpharmacologic
treatment options for the management of
complications associated with dialysis (1,7)
 Utilize resources to evaluate drug dosing during
dialysis (1,5,8)
April 2 SC Renal Transplant  Compare and contrast medications used for S. Anderson
Thur immunosuppression in a renal
3:45-5:15 transplantation(1,5,10)
PM  Create or adjust a drug therapy regimen and
monitoring plan for a given patient scenario
(1,2,3,4,5,8)
 Identify factors that cause rejection (1,10)
 Describe the most common complications
associated with immunosuppression (1,10)
Week 12 SC Pathophysiology  Define COPD and list the 2 major etiologies. Sehgal
April 7 & pharmacology
Tue 3:00- of COPD &  Differentiate between the pathophysiologies of
5:15 PM Asthma chronic bronchitis with emphysema associated
with COPD (7)

Page 12 of 18
  Define asthma and differentiate between the
pathophysiology of asthma with COPD (7)

 Explain the role of leukotrienes in the

pathophysiology of asthma (7)

 Understand how the drug therapy of asthma is

related to acute vs. chronic phases of the
process (7)

 Distinguish between the molecular mechanisms

of drugs such as adrenergic agonists with drugs
such as corticosteroids (7,8)
Wed SC Pathophysiology  Compare the pathophysiologies of allergic Sehgal
April 8 & pharmacology rhinitis with asthma (7)
3:45-5:15 of upper
PM respiratory  Choose pharmacologic agents which are
conditions: effective at preventing allergic rhinitis and tell
sinusitis, how the application of these differ from those
pharyngitis and used in symptom reduction (7)
allergic rhinitis
 Explain the mechanism of H1 receptor
antihistamines (8)

 Review agents which may be used to treat

sinusitis as well as rhinitis (8)

 Describe pharyngitis (7)

April 9 SC Pathology and  Define the two types of sleep apnea and identify Sehgal
Thur pharmacology of the most common (7)
3:45-5:15 interstitial and
PM other lung diseases  Know the pharmacologic treatments for
obstructive apnea (8)

 Define bronchiolitis and identify 2 treatment

options (7,8)

 Identify typical pharmacologic therapies used to

support patients with occupational lung diseases
(7,8,)

 Explain the pathophysiology underlying coal

worker’s pneumoconiosis.
April 10 Exam IV
Friday
8am-
10am

Page 13 of 18
Week 13 SC Drug-induced  Distinguish between drug effects on the target Sehgal
April 14 pulmonary tissues and pneumotoxic effects for
Tue 3:00- toxicities Amiodarone and bleomycin (7,8)
5:15 PM
 Describe pulmonary fibrosis (7)
April 15 SC Pathophysiology/P  Understand the etiopathology of cystic fibrosis Sehgal
Wed harmacology of (7)
3:45-5:15 Cystic Fibrosis.
PM  Choose symptoms reduced by traditional
therapies for C.F (7)

 Distinguish options for therapy of this disease

vs. poly factorial diseases (7,8)

 Analyze obstacles for using gene therapy for

C.F (7,8)

 Distinguish between successful gene delivery

and therapeutic efficacy (7,8)
April 16 No class
Thur
3:45-5:15
PM

Week 14 SC Asthma  List the factors that can trigger asthma Gillette
April 21 symptoms in patients with asthma (1)
Tue 3:00-
5:15 PM  Describe the characteristics that classify a
patient as having intermittent, mild persistent,
moderate persistent, and severe persistent
asthma (1,2)

 Classify asthma control as being well

controlled, not well controlled, or very poorly
controlled (1,2)

 Create or adjust a drug therapy regimen and

monitoring plan for a given patient scenario
(1,2,3,4,5,8)

 Describe the recommended therapy for an acute

exacerbation of asthma at home, in the
emergency department, and in the hospital
(2,3,4)
April 22 SC COPD  Apply GOLD guidelines to stage a patient with S. Anderson
Wed COPD (1,2)
3:45-5:15
PM  Create a plan or care for a patient in each stage
of COPD (1,2,3,4)
Page 14 of 18
  Identify appropriate immunizations for patients
with COPD (1,2,3,4)

 Create a plan of care for a patient experiencing

an acute exacerbation of COPD (1,2,3,4,5)
April 23 SC Allergic Rhinitis  Recommend methods to avoid explsure to S. Anderson
Thur allergens (1,5,6)
3:45-5:15  Debate the potential value of newer,
PM peripherally selective antihistamines over older
nonselective agents (2,3,4,8)
 Discuss the key points to make when
counseling a patient on the use of medications
used to treat allergic rhinitis (2,3,4,5,6)
Week 15 SC No class
April 28
Tue 3:00-
5:15 PM

April 29 SC Cystic Fibrosis  Intepret the use of the sweat chloride tests and S. Anderson
Wed know what values are considered abnormal
3:45-5:15 (1,2)
PM
 List the various goals that pertain to each organ
system (1,2)

 Discuss the components of an airway clearance

routine (1,2)

 Explain the importance of anti-inflammatory

therapies utilized in CF (5,6)

 Discuss social and quality of life issues that

impact a CF patient (5,6)
April 30 SC Review Sizemore
Thur S.Anderson
3:45-5:15 Sehgal
PM

May 4
Mon Final Exam
8am
SC = Studio Classroom

Course Evaluation (grading)

Point or Percentage Distribution:

4 Exams* = 65%
1 Cumulative Final Exam*# = 25%
Page 15 of 18
 IRATs1 = 5%
Active Learning Events/Assignments/Participation/GRATs= 5%

1. IRAT = Individual readiness assurance test

2. GRAT = Group readiness assurance test

Letter grades distribution: A = 89.50 to 100%

B = 79.50 to less than 89.50%
C = 69.50 to less than 79.50%
F = Less than 69.50%

Examination Schedule:
Examination I – February 9, 2014 – 6:00 PM – 8:00 PM
Examination II – February 27, 2014 – 11:00 AM – 1:00 PM
Examination III – March 13, 2014 – 11:00 AM – 1:00 PM
Examination IV – April 10, 2014 – 8:00 AM – 10:00 AM
Final Examination – May 4, 2014 – 8:00 AM – 10:00 AM

If you would like to formally contest a question on an exam it must be submitted in writing within 7 days of the
exam date.

Course Evaluation (assessment):

Student Evaluation:
Survey: each student will have the opportunity to evaluate each instructor as well as course
content via the school’s universal evaluation survey

Focus group: 5-6 student volunteers will serve as a weekly focus group with team leader

Faculty Evaluation: Faculty members participating in the course will attend class as often as possible
to evaluate overall performance

Assignment and examination grades will be posted in Blackboard within 7 days unless otherwise stated.

Attendance policy:
Each student is expected to attend class. Attendance at graded events is mandatory. Only University or school
of pharmacy approved excuses will be accepted. The instructor must be contacted prior to the exam, unless
circumstances are prohibitory. Please note that the student is solely responsible for any materials missed.

UNIVERSITY POLICIES

University policies regarding Academic Dishonesty, Students with Disabilities, University Computing
Services’ Acceptable Use, Affirmative Action, and Sexual Harassment can be found at
http://www.marshall.edu/wpmu/academic-affairs/policies/.

Page 16 of 18
School of Pharmacy Policies

SOCIAL JUSTICE POLICY STATEMENT

Marshall University is committed to bringing about mutual understanding and respect among all individuals and
groups at the University. As part of Marshall University, School of Pharmacy has made a commitment to social
justice. Therefore, no one will be discriminated against on the basis of race, gender, ethnicity, age, sexual
orientation, religion, social class, or differing viewpoints. Each student will be viewed as a valuable member of
this class and as the faculty for the course; I will strive to facilitate an atmosphere/learning environment where
mutual understanding and respect are actualized.

ACADEMIC, ETHICAL, AND PROFESSIONAL CONDUCT

Student expectorations for academic, ethical, and professional conduct are defined within the school’s Ethical
and Professional Conduct Policy and the university’s Academic Dishonesty Policy.

Second Chance and Remediation Policy

Second chance and remediation are mechanisms designed to assist students who have struggled within the
classroom environment in demonstrating achievement of classroom and curricular learning outcomes. These
processes are described in sections 200.001.003 (Second Chance) and 200.001.004 (Remediation) of the
Academic Standards for Grading, Progressions, Dismissal, and Re-admission Policy.

Test Security Policy

In order to ensure the security of all examinations, the School of Pharmacy has adopted the following policies:

1. Test Administration

A. Non-electronic testing
a. Students may not access any electronic equipment during the exam that has not been provided by
the faculty, including but not limited to calculators, cell phones, laptops and PDAs.
B. Electronic testing
a. Only those resources (electronic or otherwise) approved by the instructor may be used or accessed
during the testing session.
b. Students enrolled within courses using electronic testing must download and install the Respondus
Lockdown Browser. The installation will require an installation code that must be acquired from
Computing Services.

2. Test Review

A. Students will not be allowed to view any exam without direct supervision of course faculty or site
facilitator
B. Students must review tests within time specified by the course faculty.
C. Limited numbers of students may be allowed to view the exam at one time depending on office size, space,
and faculty preference.
D. Students will be allowed to review the exam only one time, and time limits may be placed on review as
specified by course faculty.

Page 17 of 18
E. NO notes can be taken by the student while reviewing the test, and students are not allowed to access any
electronics while reviewing the tests. NO copies electronic or written!
F. Individual student printouts for exams are to be retained by the faculty.
G. Faculty has the right to place further restrictions on test review as deemed necessary.

Page 18 of 18